G56W1 in Women With Postmenopausal Osteoporosis

Phase 1

Conditions: Postmenopausal Osteoporosis

Interventions: Biological: rhPTH（1-34） 28.2μg
Biological: rhPTH（1-34） 56.5μg
Biological: teriparatide acetate(Teribone™)

Registration Number: NCT03720886

Lead Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Brief Summary: This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The anticipated time on study treatment is 24 weeks, and the target sample size is 148 individuals.

Detailed Description: Not available

Recruitment & Eligibility

Status: UNKNOWN

Sex: All

Target Recruitment: 148

Inclusion Criteria

Female, capable of self - motivation , 45 years old ≤ age ≤ 75 years old.
Natural menopause for 3 years or more; or surgical menopause for 3 years or more (surgery needs to be performed after 40 years old), for women with surgical menopause, estradiol(E2)< 25 pg/ml and follicle stimulating hormone(FSH) > 40mIU/ml should be met.
Weight ≥ 40kg , 18 ≤ body mass index(BMI)≤ 30 .
Meets one of the following diagnostic criteria for osteoporosis, and ≥ 3 vertebral bodies of L1-4 can be measured by bone mineral density using the DXA method.
1. Brittle fracture of the hip or vertebral body, and the bone density measurement T- score< -1.0.
2. The T- score of the central axis bone mineral density or the 1/3 bone density of the distal radius of the tibia was ≤-2.5 measured by DXA .
3. Bone density measurements were consistent with low bone mass ( -2.5 < T- value < -1.0 ) and combined with proximal humerus, pelvic or forearm distal brittle fractures.
to participate in the trial and sign the informed consent form.

Exclusion Criteria

to have diseases affecting calcium or bone metabolism that are not effectively controlled, such as primary hyperparathyroidism or hyperthyroidism, Paget's bone disease, hypercalcemia, hypocalcemia, active urolithiasis.
Secondary osteoporosis, such as osteomalacia, rheumatoid arthritis, gout, multiple myeloma, etc.
Severe lumbar anatomical abnormalities which affecting DXA bone mineral density measurement, such as severe scoliosis.
Patients who have been treated for anti-osteoporosis before random enrollment:
1. Patients who received parathyroid hormone(PTH) therapy before random enrollment (including clinical trials of similar products).
2. Patients who received bisphosphonate injection within 1 year prior to random enrollment or received bisphosphonate oral administration within 3 months for > 2 weeks prior to enrollment.
3. Systemic treatment of androgen, estrogen, and selective estrogen receptor modulator(SERM) preparations within 3 months > 2 weeks prior to random enrollment.
4. Three months before randomized to receive of heparin, warfarin, anticonvulsants (except benzodiazepines), digoxin accumulated for> 2 weeks.
5. In the 3 months prior to random enrollment , received calcitonin, vitamin K preparation, active vitamin D3 preparation, oral or intravenous glucocorticoid treatment for > 4 weeks.
Suffering from severe kidney disease, uncontrolled high blood pressure ( ≥150/100 mmHg ), symptomatic ischemic heart disease, cerebral infarction or obliterative atherosclerosis, malignancy, and other serious underlying diseases.
Laboratory tests indicates abnormal, including any of the following indicators abnormalities (according to the normal range of each center, after consideration of the investigator with clinical considerations, such as caused by operational procedures, etc., after discussion with the sponsor, may allow retesting once) .
1. Alkaline phosphatase(ALP)>1.5 times the upper limit of normal.
2. Aspartate transaminase(AST) or alanine aminotransferase(ALT) or total bilirubin(TBIL) > 2.0 times the upper limit of normal.
3. Glycated hemoglobin(HbA1c )≥ 7.0% .
4. White blood cell(WBC)< 3.5×10^9 /L , Hb<100g/L or Plt<90×10^9 /L.
5. Thyroid-stimulating hormone(TSH)<0.01 mIU/L (mU/L) or TSH>10 mIU/L (mU/L) .
6. Parathyroid hormone(PTH)>1.5 times the upper limit of normal.
7. Serum creatinine(SCr)>1.2 times the upper limit of normal.
8. Serum total calcium(SCa)> normal upper limit.
Subjects who had significant clinical significance including HIV , hepatitis B, hepatitis C, and syphilis ( hepatitis B virus carriers can be enrolled ) .
Heavy Smoking (average of more than 10 / day) and / or alcohol addicted (converted to pure alcohol 30 ml / day or more) .
Recent drug abuse or drug dependence evidence.
Those who are allergic to test drugs / control drugs or biological products.
Included in other interventional clinical trials within 3 months of the study.
Been undergone radiation therapy for bones.
Mental illness or any cause of cognitive impairment.
Patients who were considered unsuitable for the study based on risk benefits by investigators.

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
rhPTH（1-34） 28.2μg	rhPTH（1-34） 28.2μg	Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
rhPTH（1-34） 56.5μg	rhPTH（1-34） 56.5μg	Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
teriparatide acetate(Teribone™)	teriparatide acetate(Teribone™)	Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.

Primary Outcome Measures

Name	Time	Method
The percentage change in bone density of the lumbar spine ( L1-4 ) from baseline to 24 weeks after treatment	Baseline，week 24	bone mineral density(BMD) measured by dual energy x-ray absorptiometry (DXA)

Secondary Outcome Measures

Name	Time	Method
Evaluate the rate of change of Procollagen I N-terminal peptide(PINP),Serum cross-linked C-terminal telopeptide of type I collagen(s-CTX) ,Bone alkaline phosphatase(BALP) , and blood calcium from baseline	Baseline，week 24	Central lab will be used
The percentage change of total hip bone density from baseline to 24 weeks after G56W1 treatment	Baseline，week 24	BMD measured by DXA
Maximum plasma concentration (Cmax)	Baseline，week 1，week 4，week 12，week 24	serum parathyroid hormone(PTH) will be tested for all pharmacokinetics parameters
Area under the plasma concentration versus time curve (AUC)	Baseline，week 1，week 4，week 12，week 24	serum PTH will be tested for all pharmacokinetics parameters
Elimination half-life（t1/2）	Baseline，week 1，week 4，week 12，week 24	serum PTH will be tested for all pharmacokinetics parameters
Time to maximum plasma concentration（Tmax）	Baseline，week 1，week 4，week 12，week 24	serum PTH will be tested for all pharmacokinetics parameters

Trial Locations

Locations (9): Peking Union Medical College Hospital
🇨🇳
Beijing, Beijing, China
Chongqing Three Gorges Central Hospital
🇨🇳
Wanzhou, Chongqing, China
Zhongda Hospital, Southeast University
🇨🇳
Nanjing, Jiangsu, China
Nanjing Drum Tower Hospital
🇨🇳
Nanjing, Jiangsu, China
Huadong Hospital Affiliated to Fudan University
🇨🇳
Shanghai, Shanghai, China
Shanghai Sixth People's Hospital
🇨🇳
Shanghai, Shanghai, China
The West China Second UniversityHospital of Sichuan University
🇨🇳
Chengdu, Sichuan, China
West China Hospital，Sichuan University
🇨🇳
Chengdu, Sichuan, China
Tianjin Hospital
🇨🇳
Tianjin, Tianjin, China

G56W1 in Women With Postmenopausal Osteoporosis

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts